Delving into the Latest Updates on 177Lu-DOTA-EB-FAPI with Synapse

Overview

Basic Info

Drug Type

Radionuclide Drug Conjugates (RDC), Therapeutic radiopharmaceuticals

Synonyms-

Target

FAP

Mechanism

FAP antagonists(Fibroblast activation protein alpha antagonists)

Therapeutic Areas

NeoplasmsRespiratory DiseasesEndocrinology and Metabolic Disease+ [1]

Active Indication

progressive non-small cell lung cancerFollicular AdenocarcinomaPapillary thyroid cancer+ [2]

Inactive Indication-

Originator Organization

The First Affiliated Hospital of Xiamen University

Active Organization

The First Affiliated Hospital of Xiamen University

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

An Open-Label, Non-Randomized, Dose Escalation, Single-Center, Investigator-Initiated Trial to Determine the Safety, Dosimetry, and Preliminary Effectiveness of 177Lu-DOTA-EB-FAPI in Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With Progressive Disease After Tyrosine Kinase Inhibitors Treatment

Increased fibroblast activation protein expression is positively correlated with the dedifferentiation and aggressiveness of thyroid cancer. Radiolabeled fibroblast activation protein inhibitor therapy, also known as radioligand therapy has become a novel treatment for patients with radioactive iodine refractory thyroid cancer and disease progression after first-line treatment. However, a major problem in the therapeutic use of 177Lu-DOTA-FAPI has been its short half-life and fast rate of clearance. This study was designed to evaluate the safety, tolerability, and maximum tolerated dose of a long-lasting radiolabeled fibroblast activation protein inhibitor 177Lu-DOTA-EB-FAPI in mRAIR-TC patients with PD after TKIs treatment.

Start Date15 Jun 2022

Sponsor / Collaborator

The First Affiliated Hospital of Xiamen University

NCT05963386

/ CompletedPhase 2IIT

An Open-Label, Non-Randomized, Single-Center, Investigator-initiated Phase II Trial to Determine the Efficacy and Safety of 177Lu-DOTA-EB-FAPI in Patients with Various End-stage Solid Tumors

Increased fibroblast activation protein expression is positively correlated with the aggressiveness of cancer. Radiolabeled fibroblast activation protein inhibitor therapy, also known as radioligand therapy has become a novel treatment for patients with refractory cancer and disease progression after multiple-lines treatment. However, a major problem in the therapeutic use of 177Lu-DOTA-FAPI has been its short half-life and fast rate of clearance. This study was designed to investigate the efficacy and safety of 177Lu-DOTA-EB-FAPI in patients with various solid tumors who had failed standard therapies.

Start Date22 Feb 2022

Sponsor / Collaborator

The First Affiliated Hospital of Xiamen University

100 Clinical Results associated with 177Lu-DOTA-EB-FAPI

Login to view more data

100 Translational Medicine associated with 177Lu-DOTA-EB-FAPI

Login to view more data

100 Patents (Medical) associated with 177Lu-DOTA-EB-FAPI

Login to view more data

100 Deals associated with 177Lu-DOTA-EB-FAPI

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
progressive non-small cell lung cancer	Phase 2	CN	The First Affiliated Hospital of Xiamen University	22 Feb 2022
Follicular Adenocarcinoma	Phase 1	CN	The First Affiliated Hospital of Xiamen University	15 Jun 2022
Papillary thyroid cancer	Phase 1	CN	The First Affiliated Hospital of Xiamen University	15 Jun 2022
Refractory Thyroid Gland Carcinoma	Phase 1	CN	The First Affiliated Hospital of Xiamen University	15 Jun 2022
Thyroid Cancer, Hurthle Cell	Phase 1	CN	The First Affiliated Hospital of Xiamen University	15 Jun 2022